Arsenic trioxide (As 2 O 3 ) has been used medicinally for thousands of years. Its therapeutic use in leukaemia was described a century ago. Recent rekindling in the interest of As 2 O 3 is due to its high efficacy in acute promyelocytic leukaemia (APL). As 2 O 3 has also been tested clinically in other blood and solid cancers. Most studies have used intravenous As 2 O 3 , although an oral As 2 O 3 is equally efficacious. Side effects of As 2 O 3 are usually minor, including skin reactions, gastrointestinal upset, and hepatitis. These respond to symptomatic treatment or temporary drug cessation, and do not compromise subsequent treatment with As 2 O 3 . During induction therapy in APL, a leucocytosis may occasionally occur, which can be associated with fluid accumulation and pulmonary infiltration. The condition is similar to the APL differentiation syndrome during treatment with all-trans retinoic acid, and responds to cytoreductive treatment and corticosteroids. Intravenous As 2 O 3 treatment leads to QT prolongation. In the presence of underlying cardiopulmonary diseases or electrolyte disturbances, particularly hypokalaemia and hypomagnesaemia, serious arrhythmias may develop, with torsades du pointes reported in 1% of cases. This may be related to a dosedependent arsenic-mediated inhibition of potassium ion channels that compromises cardiac repolarization. Because of slow intestinal absorption, oral-As 2 O 3 gives a lower plasma arsenic concentration, which is associated with lesser QT prolongation and hence a more favorable cardiac safety profile. As 2 O 3 does not appear to enter the central nervous system. However, if the blood brain barrier is breached, elemental arsenic may enter the cerebrospinal fluid. As 2 O 3 is predominantly excreted in the kidneys, and dose adjustment is required when renal function is impaired.
Introduction
Arsenic is infamous as a poison, but has recently gained fame as a remedy. It has featured in traditional Chinese pharmacopoeia for millennia, according to the traditional Chinese dictum of using poison against poisonous diseases [1] . In Western medicine, arsenic became popular as a drug after Dr Thomas Fowler in Edinburgh prepared a potassium bicarbonate based solution of arsenic, which was to bear his name. Arsenic also continued to be used as a poison, Napoleon Bonaparte being allegedly its victim [2] . Around the end of the nineteenth century and the turn of the twentieth century, arsenic was a standard medication for chronic myeloid leukaemia, there being no other more effective treatment. However, with the advent of modern pharmacology and chemotherapeutic agents in the latter half of the twentieth century, the use of arsenic declined, and description of its efficacy in chronic myeloid leukaemia disappeared from standard haematology textbooks after the 1950's [3] . Although rarely now used as a poison, in the Indian sub-continent alone, chronic arsenic poisoning due to drinking water contamination has been estimated to affect over 120 million people [4, 5] . There has been a rekindling in the interest of the therapeutic use of arsenic, due predominantly to the observation that arsenic trioxide (As 2 O 3 ) induced a high rate of remis-sion in patients with relapsed acute promyelocytic leukemia (APL) [6, 7] . As 2 O 3 induces partial differentiation and apoptosis in the APL cells through a variety of molecular mechanisms. Amongst these molecular actions, the targeting of the leukaemogenic fusion protein PML-RARA to proteasomal degradation is an important reason for the specificity of As 2 O 3 for APL. As 2 O 3 is now a standard drug in the treatment of newly diagnosed or relapsed APL. It is also now tested clinically in the treatment of other malignancies, notably multiple myeloma.
Owing to its notoriety as a poison, treatment with As 2 O 3 is alarming to patients and physicians alike. Therefore, a thorough understanding of the safety and potential side effects of As 2 O 3 as a therapeutic agent is necessary, in order to minimize its toxic complications.
Acute toxic effects of arsenic poisoning
Toxicities of short and long term arsenic exposure have been documented from case reports, epidemiological studies and animal experiments [8] .Up to 200 human enzymes are inactivated by arsenic. The severity of the toxicity depends on the arsenic compound, and the route, pace and duration of absorption. The acute lethal dose varied from 100 to 300 mg of elemental arsenic [9] . Oral arsenic is methylated into active metabolites in the liver. Animal studies have shown that arsenic is concentrated in the liver, urinary bladder, and lungs. Clearance from the liver and bladder is rapid, but clearance of methylated arsenic metabolites from the kidney, heart and lungs takes a longer duration [10] . Since arsenic is mainly renal excreted, haemodialysis is the most effective and rapid way of detoxification. The use of chelating agents may also help [11] . Toxicities of acute arsenic poisoning include oesophagitis, abdominal colic, diarrhoea, arrhythmia, and mental confusion [8] . Chronic arsenic toxicity, observed mainly from studies of environmental low dose arsenic exposure, include skin pigmentation, neuropathy, skin cancers, liver cirrhosis and hepatocellular carcinoma (HCC) [8] . Environmental arsenic poisoning may account for many of the cases of idiopathic Indian childhood cirrhosis [12, 13] . When arsenic is prescribed therapeutically in a controlled manner, none of these toxic side effects have been observed.
Use of arsenic as a therapeutic agent
The current therapeutic use of As 2 O 3 is limited to the treatment of malignancies. Chinese investigators in Harbin and later Shanghai have shown that intravenous (iv) As 2 O 3 at 0.07-0.17 mg·kg -1 ·d -1 is highly effective in relapsed APL, resulting in a complete remission (CR) rate of over 95% [14] .
The effect is specific, with remissions not achieved in other types of leukaemia [7] . These results have been confirmed subsequently worldwide [15, 16] . As 2 O 3 therapy is largely safe and few patients require cessation of treatment due to side effects [17] . Persistent and durable molecular remission is achieved occasionally with As 2 O 3 treatment alone [18] . Moreover, As 2 O 3 is increasingly used in combination with all trans retinoic acid (ATRA) to exploit their synergistic interactions, in the first-line treatment and maintenance of APL [1, 19] . In these studies, As 2 O 3 is administered as a daily iv infusion. The duration of iv-As 2 O 3 leading to remission ranged from 10-60 (median: 23) days [1, 19] . To obviate the problems associated with iv administration, an oral formulation of As 2 O 3 has also been prepared. It has comparable efficacy with the iv formulation, and poses no severe first-pass toxic side effects to the liver [20] . Oral-As 2 O 3 has important advantages in cost savings and patient convenience, as it can be administered in the outpatients [21] . Diarsenic tetrasulphide has also been formulated orally for APL treatment, although its low solubility means that a much larger oral dose is required [22] . Data on the use of diarsenic tetrasulphide, particularly on its safety and pharmacokinetics, are limited.
As 2 O 3 exerts differentiation and pro-apoptotic actions on APL leukaemic cells [6] . In vitro studies with cell lines and primary tumor cell cultures have also shown that other leukaemias and cancers are potentially sensitive to As 2 O 3 . These include multiple myeloma [23, 24] , myeloid leukaemias, lymphomas, squamous cell carcinomas and neuroblastomas [25] . Based on these results, clinical trials have been initiated for As 2 O 3 treatment in these malignancies.
In the last decade, thousands of patients have been treated with As 2 O 3 . Increasing numbers of clinical trials in other types of malignancies have suggested that As 2 O 3 might also be therapeutically useful. Therefore, it will be opportune to review its side effects and toxicity profile.
Arsenic pharmacokinetics
After an iv infusion of As 2 O 3 , the plasma arsenic level reaches its peak in the first hour. At a dose of 10 mg, the median peak plasma arsenic level as measured by gas phase chromatography was 6.8 (5.54-7.30 ) µmol/L in a study involving 15 patients [14] . However, with the more specific and accurate methods of atomic absorption spectrometry or inductively coupled plasma mass spectrometry, the peak arsenic level after a one-hour iv infusion of As 2 O 3 has been found to range from 0.5-2 µmol/L [20] . Repeated administration of As 2 O 3 has little effect on the pharmacokinetic profile of iv-As 2 O 3 . Slightly less than 10% of the total dose of As 2 O 3 is renal excreted. Tissue accumulation of arsenic occurs during As 2 O 3 treatment. After completion of As 2 O 3 therapy, urinary arsenic excretion continues for some time. At about four weeks after cessation of As 2 O 3 , plasma arsenic level declines to baseline levels, and arsenic urinary excretion stops.
The pharmacokinetics of oral-As 2 O 3 follows a similar pattern. The peak plasma arsenic level achieved with the same dosage of oral-As 2 O 3 (10 mg) is lower at 0.2-0.6 µmol/L. However, owing to gradual intestinal absorption, the area-under-the-curve (AUC) absorption of oral-As 2 O 3 is comparable with that of iv-As 2 O 3 , implying that the bioavailability of oral-As 2 O 3 is comparable with iv-As 2 O 3 [20] . The much lower peak arsenic plasma level after oral-As 2 O 3 administration is an important reason for the improved safety as compared with iv-As 2 O 3 . Oral-As 2 O 3 is also predominantly renal excreted.
Hepatic toxicity
Liver function tests (LFT) derangement is one of the commonest side effects. Typically, there is a hepatitis with increases in alanine and aspartate aminotransferases, starting about five to ten days after drug administration. The peak transaminase levels rarely exceed five times the upper reference value [21] . Increases in bilirubin and ductal enzymes including alkaline phosphatase and γ-glutamyl transpeptidase are uncommon, and if present should prompt investigations for other causes of cholestasis. A few cases of fulminant hepatic failure had been reported when As 2 O 3 was used in patients with newly diagnosed APL [14] . However, this phenomenon has not been confirmed subsequently, suggesting that the observation is fortuitous only. As 2 O 3 can be considered to be safe in all stages of APL.
When the transaminase elevations are less than three times normal, our experience shows that As 2 O 3 therapy can be continued at half the original dose. The liver function usually normalizes within a week, and resumption of fulldose treatment or at the reduced dose is then well tolerated [14] . This transient hepatitis may or may not recur during subsequent As 2 O 3 treatment. However, when the transaminases exceed three times normal, temporary cessation of As 2 O 3 treatment may be needed. The hepatitis usually resolves within a week, and treatment at half the original dose, with gradual escalation to full dose, can be reinstated.
Different from iv-As 2 O 3 , the full dose of oral-As 2 O 3 passes first through the portal circulation and therefore the liver. Despite this first-pass effect, oral-As 2 O 3 does not cause more liver toxicity, so that the frequency and severity of LFT derangement are comparable with iv-As 2 O 3 .
Data from chronic arsenic poisoning suggest that liver fibrosis, cirrhosis and hepatocellular carcinoma may occur [5, 26, 27] . Therefore, the toxicity of prolonged therapeutic use of As 2 O 3 may require close monitoring. So far, cirrhosis and hepatocellular carcinoma in after treatment with therapeutic doses of As 2 O 3 have not been reported. In chronic carriers of the hepatitis B virus (HBV), lamivudine prophylaxis to prevent viral reactivation has been adovcated [28] , although such a strategy has not been validated in control trials. Since both HBV and As 2 O 3 predispose to cirrhosis and hepatocellular carcinoma [29] , it may be prudent to prescribe prophylactic anti-viral treatment to avoid potential synergistic As 2 O 3 and HBV hepatic damage.
Finally, other hepatotoxic drugs used in the clinical course of leukaemia, including antibiotics and the azole anti-fungal drugs, should also be used with caution during As 2 O 3 therapy.
Dermatologic toxicity
Chronic arsenic exposure results in various skin manifestations, including hyperpigmentation, keratosis, bowenoid lesions and squamous cell carcinoma. The therapeutic use of As 2 O 3 results in cumulative doses well below that reported for environmental or occupational arsenic exposure that leads to these skin manifestations [5] . The commonest dermatologic problem during As 2 O 3 treatment is increased skin pigmentation [27] . So far, squamous cell carcinoma has not been reported. Abnormal pigmentation is reversible after cessation of As 2 O 3 treatment. If severe or persistent pigmentation occurs, other causes potentially related to the underlying leukaemia, including porphyria and hemosiderosis, will have to be excluded [30] . Rashes are the next commonest problem. A late-onset painful, erythematous rash can be seen after prolonged arsenic treatment, which may be related partly to the vasoconstrictive effects of arsenic [31] . The concomitant use of ATRA may also worsen the rashes. In severe cases, temporary dose reduction or even cessation of As 2 O 3 may be required. An allergic type of morbilliform to pruritic rash has been observed [32] . Rashes respond well to corticosteroid treatment, and As 2 O 3 treatment can be continued without interruption. Swelling of hands, legs and face has also been found [33] , which may be related to fluid retention as part of the APL differentiation syndrome.
Another intriguing side effect of As 2 O 3 treatment is reactivation of latent herpes virus infection [34] . Both herpes simplex and herpes zoster reactivation may occur. In fact, herpetic reactivation had been found to complicate arsenic poisoning since the late nineteenth century. During the British beer arsenic-poisoning episode of 1900, herpetic skin eruptions increased to epidemic proportions. Dr E.S. Reynolds, who investigated these cases of "alcoholic neuritis", was prompted by the frequent shingles (herpes zoster) in the victims to conclude that "there must be arsenic in the beer the people are drinking … because, of all known drugs arsenic is the only drug which causes shingles." [35] . During As 2 O 3 treatment, herpes zoster reactivation occurs in up to 25% of patients within the first year of treatment [36] . Recognition of the association is important, because timely treatment of herpes zoster may shorten the duration of the attack and decrease post-herpetic complications.
Hematologic toxicity
Because of a partial differentiation effect of As 2 O 3 on the leukemic clone, leucocytosis occurs commonly. On continuation of As 2 O 3 therapy, suppression of the leukaemic clone may lead to leucopenia. With haematologic remission and cessation of As 2 O 3 treatment, leucopenia recovers quickly. In As 2 O 3 maintenance treatment during remission, which lasts two weeks only, leucopenia rarely if ever develops [17] . In patients with other malignancies involving the marrow, including acute leukaemia, myelodysplasia, myeloma and lymphoma [37, 38] , continuous daily treatment with As 2 O 3 (10 mg daily) may cause mild [24] to severe pancytopenia [39] . Indeed, myelosuppression is the main dose-limiting side effect in patients treated with As 2 O 3 for leukaemias other than APL [37, 38] . Concomitant administration of other myelosuppressive drugs may further aggravate the myelotoxicity. Therefore, As 2 O 3 dosage may have to be reduced when concurrent chemotherapy or radiotherapy is used. In severely leucopenic cases, treatment with haematopoietic growth factors such as granulocyte colony stimulating factor rapidly restores normal leucocyte counts.
Cardiac toxicity
At therapeutic doses, As 2 O 3 treatment results in prolongation of the QT interval [15, 32, 40] . Electrocardiographic (ECG) studies in patients receiving iv-As 2 O 3 have shown significant QT interval prolongation in 35% of cases, with symptomatic torsades de pointes in 1-3% of cases [15, 41] . Continuous ambulatory ECG monitoring detects various cardiac dysrrhythmias in higher frequencies [32] . The majority of these ECG abnormalities are asymptomatic. There are only few reports of patients with suspected cardiac death during As 2 O 3 treatment. Even in these cases, arrhythmia attributable entirely to arsenic has not been unequivocally documented [42, 43] . These cardiac toxicities have been investigated in vitro. Guinea pig papillary muscles showed delayed cardiac repolarization during As 2 O 3 administration at 10-50 mg/kg [44] . Rabbit heart, however, did not show any detectable conduction abnormalities with short-term perfusion of As 2 O 3 to up to 30 µmol/L, and cardiac conduction and repolarization abnormalities only occurred with short-term infusion of 300 µmol/L of As 2 O 3 [45] . On chronic administration of As 2 O 3 at 30 µmol/L, QT prolongation and polymorphic ventricular tachycardia might result [45] . These conduction abnormalities may be due to decrease in surface expression of the potassium channel I Kr protein hERG. This is related to arsenic-induced interference of hERG trafficking, as a result of inhibition of hERG-chaperone complexes formation [46] . The As 2 O 3 concentration required to reduce hERGchaperone formation by 50% was 3 µmol/L. Further studies have shown that the I Kr and I Ks potassium channels were inhibited by As 2 O 3 . The IC 50 for I Kr was 0.14±0.01 µmol/L, and that for I Ks 1.13±0.06 µmol/L. However, another potassium channel I K-ATP was activated by As 2 O 3 at 1 µmol/L [47] . Hence, the net effects may depend on a balance of activation and blockade of multiple repolarization potassium channels. It must be noted that the crucial observation of all these studies is that cardiac conduction defects are dependent on As 2 O 3 concentrations, with a much increased risk when it exceeds 1 µmol/L.
Pharmacokinetic studies have shown that oral-As 2 O 3 results in a lower peak plasma arsenic level, typically below 1 µmol/L (usually ranging from 0.2-0.6 µmol/L). This concentration falls well below 1-30 µmol/L required to lead to cardiac conduction defects in vitro. Indeed, continuous ambulatory ECG monitoring in patients on oral-As 2 O 3 has shown that although QTc is prolonged during As 2 O 3 administration, QTc prolongation >30 milliseconds only occurs at one time-point (2 hours) after oral-As 2 O 3 , resulting in QTc >500 milliseconds in about 20% of patients, all within 4 hours of oral-As 2 O 3 administration. No ventricular proarrhythmias are observed [48] . The more favorable cardiac safety profile of oral-As 2 O 3 may be due to the much lower plasma arsenic levels reached during oral As 2 O 3 administration.
In most of the cases of symptomatic cardiac arrhythmias reported previously, co-existing risk factors existed, including electrolyte abnormalities such as hypokalaemia and hypomagnesaemia, impaired cardiac function due to underlying heart diseases, and old age. Previous anthracycline exposure, however, did not appear to be important [49] . Although the risk of cardiac arrhythmias is minimal for pa-tients without underlying heart diseases, certain precautions are nevertheless prudent. Firstly, As 2 O 3 dosage should be reduced to the minimal effective amount, especially in elderly patients with impaired renal function. Secondly, concurrent drugs known to prolong the QT interval, including type I anti-arrhythmic agents, anti-histamines and tricyclic antidepressants, should be avoided [50] . Thirdly, electrolyte levels, especially potassium and magnesium, should be regularly tested and maintained at normal levels. Finally, regular ECG monitoring during the initiation of As 2 O 3 treatment is needed, until the risks of arsenic-induced arrhythmia are clarified. Patients should be fully informed of the risks of arrhythmias, and cardiac symptoms including palpitations should be prompted reported. The efficacy of prophylactic anti-arrhythmic agents in symptomatic cases is undefined [46] . Finally, oral-As 2 O 3 , with its much more favorable cardiac safety profile, may be the preferred formulation for long-term As 2 O 3 therapy [48] .
Leucocytosis and the APL differentiation syndrome
Leucocytosis and the APL differentiation syndrome are important complications during the induction treatment of APL with As 2 O 3 , occurring in 37-58% of cases [15, 32, 51] . The two conditions are closely related. Both complications occur only in APL, and have not been reported after As 2 O 3 treatment in other leukaemias and malignancies. A rapid increase in leucocyte and promyelocyte counts is reported in up to 50% of APL patients on As 2 O 3 . This may be accompanied by fever, fluid retention, pulmonary infiltrates, elevated lactate dehydrogenase levels, and occasionally pleural and pericardial effusions [33] . The clinical and laboratory features may be indistinguishable from the ATRA-syndrome that occurs during ATRA treatment of APL, where similar problems develop as the leukaemic clone differentiates and proliferates. The APL differentiation syndrome usually occurs within the first two weeks of As 2 O 3 treatment, during which regular monitoring of the leucocyte count is mandatory. However, unlike the ATRA syndrome, As 2 O 3 -induced APL differentiation syndrome is rarely if ever life-threatening.
The early recognition of the As 2 O 3 -induced APL differentiation syndrome is critical to its subsequent successful treatment. Dexamethasone leads to symptomatic improvement, and may be used to tide over the whole period of leucocytosis until the leucocyte count falls later due to arsenic-induced apoptosis of the APL cells. Practically, however, cyto-reduction with chemotherapy is more effective and safe. Drugs including hydroxyurea, daunorubicin, idarubicin and mitoxantrone have all been successfully used. The current recommendation is to start chemotherapy once the leucocyte count rises above 5×10 9 -10×10 9 /L. Since an anthracycline is used in almost all regimens for induction treatment of APL, it will be appropriate to start the drug early during the leucocytosis. Another reason for early treatment of leucocytosis is because high leucocyte counts have been associated with central nervous system (CNS) deposits and infarction [52] , and possibly extramedullary relapses in the future. It will be prudent to withhold As 2 O 3 therapy if clinical signs of the APL differentiation syndrome occur. Subsequent to successful treatment of the syndrome, the re-institution of As 2 O 3 is not compromised.
Neurologic toxicity
Peripheral neuropathy is reported in up to 10% of As 2 O 3 treated patients [18, 32] . The incidence may be higher when other predisposing conditions are present, including old age, diabetes mellitus, multiple myeloma, and the concurrent administration of neurotoxic drugs. A glove and stocking sensory neuropathy is typical, with electrophysiological studies showing reduced sensory action potentials with delayed conduction. Muscle atrophy has been reported in occasional cases after prolonged exposure [33] . Gradual improvement occurs when As 2 O 3 is reduced in dosage or stopped. Sural nerve biopsies in a few severe cases have not shown specific histopathological features. Severe functional deficits are unusual, and the presence of serious neuropathies during As 2 O 3 treatment should prompt investigations for other causes.
The blood brain barrier prevents heavy metals, including arsenic, from penetrating the CNS. Therefore, CNS side effects and encephalopathies during As 2 O 3 therapy have not been reported. Hence, mental confusion in a patient on As 2 O 3 should lead to investigations for other causes, such as CNS leukaemia, viral encephalitis, alcoholism or metabolic derangements [30] . For similar reasons, the CNS may be a sanctuary site for leukaemic cells, and isolated CNS relapse in patients who have remitted following As 2 O 3 treatment has been described frequently [53] . Suspected Wernicke's encephalopathy associated with As 2 O 3 treatment has been reported [54] . However, abnormalities in thiamine pyrophosphate and erythrocyte transketolase levels in consecutive patients on prolonged As 2 O 3 treatment have not been observed, so that routine vitamin supplements do not seem to be warranted. Long-term follow-up has not shown unusual CNS manifestations in patients after chronic treatment with As 2 O 3 , although behavioral abnormalities have been reported in animals with chronic arsenic exposure since birth [55] . Entry of arsenic into the CNS, however, may occur when the blood brain barrier is breached. In a case of meningeal relapse of APL treated with oral-As 2 O 3 , penetration of arsenic into the cerebrospinal fluid to therapeutically meaningful levels has been observed [56] . Therefore, in patients in whom the blood brain barrier is compromised, As 2 O 3 will have to be administered with caution [57] . A prominent but innocuous side effect is severe headache when As 2 O 3 is administered together with ATRA [58] . Computerized tomographic scan and fundoscopic examination have occasionally shown signs of pseudotumor cerebri [59] . Although this side effect is distressful and alarming, the headache responds swiftly to analgesic treatment and dose splitting of ATRA or As 2 O 3 , and no long-term sequelae have been reported.
Miscellaneous toxicities
Gastrointestinal upset is frequently reported even with iv-As 2 O 3 [32] . For patients on oral-As 2 O 3 , mild nausea and dyspepsia are frequent [21, 22] . Most patients respond to symptomatic treatment and cessation or dose reduction of As 2 O 3 is unnecessary. Carcinogenicity and mutagenicity are common concerns for anti-neoplastic agents. In populations exposed to chronic environmental arsenic poisoning, a higher incidence of skin and liver cancer is observed, together with chromosomal instability [60] . An increased incidence of cancer of the skin, lung and liver has also been reported after industrial and agricultural arsenic exposure [61, 62] . The risk of secondary cancers after As 2 O 3 treatment is undefined. Solid tumors might be a chance occurrence in As 2 O 3 -treated patients [63] . Arsenic is a known mutagen in mouse embryos, especially with concomitant folate deficiency [64] . There is no experience of the use of As 2 O 3 in pregnant woman, so that the fetal side effects of therapeutic As 2 O 3 are unknown. Arsenic is excreted in the milk and breast-feeding should be avoided during As 2 O 3 treatment.
Dose reduction of As 2 O 3
The side effects of As 2 O 3 are dose-related. The predominant renal excretion of arsenic means that in patients with impaired kidney function, As 2 O 3 dosage should be reduced. With appropriate dose adjustment and monitoring of arsenic level, a patient on continuous ambulatory peritoneal dialysis with relapsed APL had been successfully treated with oral-As 2 O 3 [65] . Due to the relatively fewer side effects as compared with chemotherapy, As 2 O 3 is the drug of choice for treating APL in elderly patients [66] . However, the volume of distribution is lower in elderly patients, so [40] A et al [51] et al [18] et al [14] et al [32] et al [37] B et al [38] C et al [15] et al [49] et al D   Number of patients  99  23  12  58  14  11  28  40  18  144  Adverse side effects  Thrombocytopenia  ------57%  --13%  Neutropenia  ------50%  8%  -22%  Zoster varicella  ------0%  --25%  QT prolongation  36%  --14%  92%  44%  4%  63%  33%  36%  Headache  ------7%  60%  -24%  Hepatitis  ---38%  --0%  25%  -53%  Nausea/dyspepsia  ---24%  50%  55%  14%  75%  -56%  Neuropathy  --17%  -21%  27%  18%  42%  -12%  APL differentiation  -58%  -59%  36%  56%  0%  25%  -58%  syndrome  Edema  ---9%  21%  18%  57%  -44%  12%  Skin rashes  ---26%  29%  56%  46%  43%  -13% A: patients with cancers; B: patients with acute myeloid leukemia (AML); C: patients with myelodysplastic syndrome (MDS); D: patients with APL, AML, MDS and lymphomas -: not available that the arsenic concentration may be higher for the same dosage of As 2 O 3 . It may be prudent to reduce to half the dose of As 2 O 3 for patients above the age of 70 years. When prolonged administration of As 2 O 3 is planned, especially for myeloma, myelodysplasia or low-grade lymphoma, the cumulative dosage and tissue concentration of arsenic becomes an important issue. In this connection, it is interesting to note that a lower As 2 O 3 dosage of 0.8 mg·kg -1 ·d -1 has been reported to be equally effective for APL [67] .
Conclusions
Arsenic has a remarkable position in medicine. It is both poisonous and therapeutically useful. Its efficacy in differentiating APL cells makes it the treatment of choice for relapsed cases, with the possibility of replacing chemotherapy in frontline and maintenance treatment. The toxicity profile of both iv-and oral-As 2 O 3 is acceptable compared with most chemotherapy regimens [68] . The frequencies of the various side effects in studies involving APL and patients with other malignancies are summarized in Table 1 . Safety may be enhanced if dosing precautions are rigorously adhered to. Although cardiac toxicity is a major concern, the frequency of life-threatening arrhythmia is low, becoming insignificant with oral-As 2 O 3 . Most of the safety data are derived from APL treatment with As 2 O 3 . Whether the risk-benefit profile is applicable to other diseases remains to be clarified.
